Indivior stock gains on raised 2026 guidance and Supernus deal
Published on 09/04/2026 at 20:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Indivior stock (ISIN GB00BYZ0C031) is in focus after Indivior Pharmaceuticals, Inc. reported its second-quarter 2026 results on August 3, 2026 and raised its full-year 2026 financial guidance, alongside progress on its planned combination with Supernus Pharmaceuticals, Inc., according to a company release dated August 3, 2026.
Q2 2026 figures and guidance raise
According to Indivior's second-quarter 2026 financial results, the company ended the quarter on June 30, 2026 with continued revenue growth and a higher outlook for the full year 2026.
In the second quarter ended June 30, 2026, Indivior repurchased 4,664,540 shares at an average price of 37.52 USD, for a total consideration of 175 million USD, as stated in the same August 3, 2026 release; year-to-date, by June 30, 2026, the company had repurchased 8,638,693 shares at an average price of 34.73 USD, totaling 300 million USD, highlighting an active capital-return program.
Capital returns and Supernus merger context
The merger plan with Supernus Pharmaceuticals, Inc. is also central to the current investment story: Indivior noted that a definitive joint proxy statement and prospectus will be sent to Indivior and Supernus stockholders in connection with the proposed transaction, with further documents to be filed with the US Securities and Exchange Commission, according to the August 3, 2026 communication.
For investors, the scale of the buyback underscores management's confidence in the equity story: comparing the year-to-date average repurchase price of 34.73 USD to the second-quarter average of 37.52 USD shows that Indivior has been willing to buy shares at roughly 8 percent higher levels in the more recent quarter, based on the same data.
More background on Indivior stock
Investors can find additional company disclosures, historical filings and further context on Indivior stock and its planned merger with Supernus via the dedicated topic page and the company investor relations site.
Representative product focus
Indivior's core business centers on treatments for opioid use disorder and related addictions, with its buprenorphine-based therapies forming a key revenue pillar; this therapeutic focus remains important context for assessing how the merger with Supernus and the expanded neurological and psychiatric portfolio could change the long-term profile of Indivior's product mix.
Stock perspective and current trading
As of September 4, 2026, investors looking at Indivior stock will weigh the raised full-year 2026 guidance, the substantial share repurchases totaling 300 million USD by June 30, 2026, and the strategic value of the planned Supernus merger when considering the current price level and valuation.
Indivior stock key data
- Company: Indivior plc
- ISIN: GB00BYZ0C031
- Ticker: INDV
- Trading venue: NASDAQ (US listing)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: None of the major DAX, SMI, ATX or S&P 500 indices
